Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | TP53 |
Variant | positive |
Impact List | unknown |
Protein Effect | unknown |
Gene Variant Descriptions | TP53 positive indicates the presence of the TP53 gene, mRNA, and/or protein. |
Associated Drug Resistance | |
Category Variants Paths |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
TP53 positive | Advanced Solid Tumor | sensitive | MVAp53 | Phase I | Actionable | In a phase I study, Ankara (MVAp53) demonstrated safety and efficacy in patients with metastatic colon, gastric and pancreas cancer stained positive for p53 (J Clin Oncol 31, 2013 (suppl; abstr 3089)). | detail... |
TP53 positive | Advanced Solid Tumor | predicted - sensitive | p28 | Phase I | Actionable | In a Phase I trial, treatment with p28 was well-tolerated and demonstrated preliminary efficacy in patients with Tp53-positive advanced solid tumors, with complete response in 6% (1/15), partial response in 20% (3/15), and stable disease in 46% (7/15) of patients (PMID: 23449360). | 23449360 |
TP53 positive | Advanced Solid Tumor | sensitive | Serdemetan | Phase I | Actionable | In a Phase I trial, Serdemetan (JNJ-26854165) treatment increased Tp53 expression in tumor and surrogate tissue, resulted in partial response in 1.8% (1/57) and stable disease in 38.6% (22/57) of patients with advanced solid tumors (PMID: 21831953). | 21831953 |
TP53 positive | breast cancer | sensitive | Serdemetan | Phase I | Actionable | In a Phase I trial, Serdemetan (JNJ-26854165) treatment induced a 102% increase of Tp53 expression in tumor tissue, resulted in partial response in a patient with breast cancer (PMID: 21831953). | 21831953 |
TP53 positive | ovarian cancer | predicted - sensitive | NU6027 + Temozolomide | Preclinical - Cell culture | Actionable | In a preclinical study, NU6027 enhanced the efficacy of Temodar (temozolomide) in ovarian cancer cells with mismatch repair activity and positive for TP53 in culture, demonstrating a 50% greater decrease in cell survival compared to Temodar (temozolomide) alone (PMID: 21730979). | 21730979 |